What Makes Corcept Therapeutics (CORT) a Good Investment Bet?

Yahoo Finance07:39 ET

6 Analysts Have This To Say About Corcept Therapeutics

During the last three months, 6 analysts shared their evaluations of Corcept Therapeutics (NASDAQ:CORT), revealing diverse outlooks from bullish to bearish.The table below provides a snapshot of their

BenzingaJun 17 15:00 ET

Corcept Therapeutics Is Maintained at Buy by Truist Securities

Corcept Therapeutics Is Maintained at Buy by Truist Securities

Dow JonesJun 17 11:37 ET

Corcept Therapeutics Insiders Sold US$1.6m Of Shares Suggesting Hesitancy

Many Corcept Therapeutics Incorporated (NASDAQ:CORT) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. Knowing whether insiders are buying is u

Simply Wall StJun 17 09:08 ET

Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $65

Truist Financial analyst Joon Lee maintains $Corcept Therapeutics(CORT.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate of 48.3%

moomoo NewsJun 17 07:33 ET · Ratings

Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $65

Truist Financial analyst Joon Lee maintains $Corcept Therapeutics(CORT.US)$ with a buy rating, and sets the target price at $65.According to TipRanks data, the analyst has a success rate of 48.3% and

moomoo NewsJun 17 06:31 ET · Ratings